A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620670
Title:
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Authors:
Marlow, R.; Kuriyakose, S.; Mesaros, N.; Han, H.H.; Tomlinson, Richard; Faust, S. N.; Snape, M. D.; Pollard, A. J.; Finn, A.
Abstract:
To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPVR (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV).
Citation:
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. 2018, 36 (17):2300-2306 Vaccine
Publisher:
Elsevier
Journal:
Vaccine
Issue Date:
Apr-2018
URI:
http://hdl.handle.net/11287/620670
DOI:
10.1016/j.vaccine.2018.03.021
PubMed ID:
29576304
Additional Links:
https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(18)30366-9
Type:
Journal Article; Randomized Controlled Trial
Language:
en
ISSN:
1873-2518
Appears in Collections:
Paediatrics; 2018 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMarlow, R.en
dc.contributor.authorKuriyakose, S.en
dc.contributor.authorMesaros, N.en
dc.contributor.authorHan, H.H.en
dc.contributor.authorTomlinson, Richarden
dc.contributor.authorFaust, S. N.en
dc.contributor.authorSnape, M. D.en
dc.contributor.authorPollard, A. J.en
dc.contributor.authorFinn, A.en
dc.date.accessioned2018-05-03T14:02:45Z-
dc.date.available2018-05-03T14:02:45Z-
dc.date.issued2018-04-
dc.identifier.citationA phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. 2018, 36 (17):2300-2306 Vaccineen
dc.identifier.issn1873-2518-
dc.identifier.pmid29576304-
dc.identifier.doi10.1016/j.vaccine.2018.03.021-
dc.identifier.urihttp://hdl.handle.net/11287/620670-
dc.description.abstractTo evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPVR (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV).en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0264-410X(18)30366-9en
dc.rightsArchived with thanks to Vaccine. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/en
dc.subjectWessex Classification Subject Headings::Paediatricsen
dc.titleA phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.en
dc.typeJournal Articleen
dc.typeRandomized Controlled Trialen
dc.identifier.journalVaccineen
dc.type.versionPublisheden

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.